Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

NCT01559935

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Weill Cornell Medical College New York, United States

View Trial Details

Active, Not Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04007029

Conditions: CD19 Positive, CD20 Positive, Chronic Disease, +33 more
Locations: UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, Not Recruiting

A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

NCT04671693

Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Hematologic Diseases, +24 more
Locations: Centre Leon Berard Lyon, France

View Trial Details

Active, Not Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083

Conditions: Behavior, Blood Protein Disorders, Cardiovascular Diseases, +20 more
Locations: Highlands Oncology Group Fayetteville, Arkansas, United States

Cancer Specialists of North Florida Jacksonville, Florida, United States

Misson Cancer + Blood Des Moines, Iowa, United States

Hematology-Oncology Associates of Central New York East Syracuse, New York, United States

View Trial Details

Active, Not Recruiting

Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)

NCT07154537

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: National Taiwan University Hospital Taipei, Taiwan

View Trial Details

Active, Not Recruiting

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

NCT03150329

Conditions: Grade 3b Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +25 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, Not Recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04665765

Conditions: Diffuse Large B-Cell Lymphoma Unclassifiable, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations: City of Hope Medical Center Duarte, California, United States

Emory University Atlanta, Georgia, United States

View Trial Details

Active, Not Recruiting

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

NCT04501939

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: UCSD Koman Family Outpatient Pavilion San Diego, California, United States

View Trial Details

Active, Not Recruiting

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hematologic Malignancies, +12 more
Locations: University of Chicago Medical Center Chicago, Illinois, United States

Weill Cornell Medical College New York, United States

View Trial Details

Active, Not Recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: Research Site Goodyear, Arizona, United States

Research Site Phoenix, Arizona, United States

Research Site Anaheim, California, United States

Research Site Los Angeles, California, United States

View all 155 locations

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions